Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

32.71
Delayed Data
As of Jan 23
 -0.52 / -1.56%
Today’s Change
32.11
Today|||52-Week Range
64.31
-9.77%
Year-to-Date
3 Incredibly Cheap High-Yield Dividend Stocks
Jan 22 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan 13 / Zacks.com - Paid Partner Content
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Jan 19 / Zacks.com - Paid Partner Content
New Strong Sell Stocks for January 11th
Jan 11 / Zacks.com - Paid Partner Content
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
Jan 19 / Zacks.com - Paid Partner Content
Trump threat fails to halt drug price hikes in 2017
Jan 04 / CNNMoney.com
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
Jan 13 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close33.23
Today’s open33.08
Day’s range32.11 - 33.10
Volume14,134,967
Average volume (3 months)9,329,247
Market cap$33.7B
Dividend yield4.16%
Data as of 4:02pm ET, 01/23/2017

Growth & Valuation

Earnings growth (last year)-48.62%
Earnings growth (this year)-5.41%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)-3.22%
P/E ratio18.9
Price/Sales2.89
Price/Book1.14

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd+0.38+1.19%
OASMOasmia Pharmaceutica...-0.16-5.35%
Data as of 4:14pm ET, 01/23/2017

Financials

Next reporting dateFebruary 9, 2017
EPS forecast (this quarter)$1.36
Annual revenue (last year)$19.6B
Annual profit (last year)$1.6B
Net profit margin8.09%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Erez Vigodman
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Tel Aviv

Forecasts


Search for Jobs